Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

23.81 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
After the closing bell, Merck said the two parties were discussing a deal at around $47 per share. 
Via Stocktwits
Most active S&P500 stocks in Thursday's session
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China. 
Via Benzinga
5 All-Weather Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Economy
2 No-Brainer Stocks to Buy With Less Than $30
Via The Motley Fool
Topics Intellectual Property
3 Reasons VTRS is Risky and 1 Stock to Buy Instead
Viatris’s stock price has taken a beating over the past six months, shedding 33% of its value and falling to $7.69 per share. This was partly due to its softer quarterly results and might have... 
Via StockStory
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
Via The Motley Fool
Topics Government Stocks World Trade
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
Pfizer Declares Second-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Looking for the most active stocks in the S&P500 index on Wednesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace... 
Via Chartmill
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
From Pfizer Inc.
Via Business Wire
Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data. 
Via Stocktwits
Topics Government
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up. 
Via The Motley Fool
S&P 500 Sell-Off: 2 Ultra-High-Yield Dividend Stocks That Make for No-Brainer Buys
Two brand-name, time-tested companies -- sporting an average yield of 7% -- are ripe for the picking amid a historic bout of volatility on Wall Street. 
Via The Motley Fool
Topics Stocks
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
Forecasting The Future: 6 Analyst Projections For Pfizer
 
Via Benzinga
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Pfizer Inc (NYSE:PFE) is scheduled to release its first quarter 2025 earnings on 29 April. 
Via Benzinga
Topics Earnings
How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock
 
Via Benzinga
Topics Retirement
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
3 Ultra-High-Yield Dividend Stocks to Buy Right Now That Are Dirt Cheap
Via The Motley Fool
Topics Economy Energy
A Once-in-a-Decade Opportunity: 3 Magnificent Stocks Down Between 40% and 73% to Buy Right Now
Via The Motley Fool
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Topics Economy Government
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.